Streetbeat News

Stock Prices

PTC

Rosenblatt has reaffirmed its Buy rating on PTC (NASDAQ:PTC), increasing the price target from $166.00 to $195.00. Despite a recent 2.02% decline in PTC's stock price to $177.00, the new target suggests a potential 10.17% upside. PTC specializes in high-end CAD and PLM software, along with IoT and AR solutions, primarily serving North America and Europe.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

KPRX

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares surged after announcing a private placement of up to $45 million and an exclusive license and development agreement with Théa Open Innovation SAS. The deal includes an upfront payment of $16 million to Kiora, potential milestone payments of up to $285 million, and tiered royalties on net sales. Additionally, Kiora will issue 15,800,000 shares and warrants to institutional investors for approximately $15 million, with potential future proceeds of $30 million from warrant exercises. KPRX's stock is currently trading above its 200-day moving average, indicating a bullish signal.

Portfolio Pulse from Erica Kollmann

February 01, 2024 | 4:57 pm

KPRX

Kiora Pharmaceuticals' stock is trading higher following the announcement of a private placement worth up to approximately $45 million.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 4:56 pm

CAH

Cardinal Health Inc (NYSE:CAH) reported a 38% Y/Y increase in Q2 FY24 adjusted EPS to $1.82, surpassing consensus estimates. Sales rose 12% to $57.45 billion, also beating expectations. The pharmaceutical segment saw a 12% increase, while the Medical segment grew by 3%. Cardinal Health announced the acquisition of Specialty Networks for $1.2 billion, aiming to expand its specialty therapeutic areas. The company raised its FY24 adjusted EPS guidance and forecasts sales growth in its Pharmaceutical and Specialty Solutions and GMPD segments. Despite the positive report, CAH shares dropped 4.30% to $104.49.

Portfolio Pulse from Vandana Singh

February 01, 2024 | 4:52 pm

CTVA

Corteva, Inc. (NYSE:CTVA) shares rose after reporting Q4 financial results surpassing analyst estimates and announcing a $1 billion repurchase plan. Adjusted earnings were 15 cents per share, a slight decrease from the previous year, with sales also seeing a minor decline. The repurchase plan is set for 2024. Mizuho analyst Chris Parkinson maintained a Buy rating but lowered the price target from $59 to $56. Corteva's stock is trading above its 50-day moving average but below its 52-week high.

Portfolio Pulse from Erica Kollmann

February 01, 2024 | 4:51 pm

ORCL

Oracle's shares are experiencing an uptick following the announcement that SmarTone Telecommunications has chosen Oracle to upgrade its Business Support System. This partnership highlights Oracle's continued relevance and competitiveness in providing enterprise solutions.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 4:51 pm

AAPL

QCOM

Qualcomm Inc (QCOM) shares fell despite beating Q1 expectations and extending its deal with Apple Inc (AAPL). Analysts remain positive, raising price targets and highlighting strong Android demand, automotive growth, and a recovery in the IoT sector. However, Huawei's re-entry into the Chinese 5G market is flagged as a key risk.

Portfolio Pulse from Priya Nigam

February 01, 2024 | 4:47 pm

AS

Amer Sports has indicated a price range of $13.10-$13.35 for 1.5 million shares.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 4:47 pm

KRE

NYCB

Regional bank stocks, including New York Community Bancorp (NYSE:NYCB), have plunged due to concerns over commercial real estate exposure. The SPDR S&P Regional Banking ETF (NYSE:KRE) fell over 11% in two days, marking its worst slump since March 2023. Analysts have downgraded NYCB's price target and expressed concerns over the sector's exposure to commercial real estate loans, with NYCB having the highest concentration at 56% of total loans.

Portfolio Pulse from Piero Cingari

February 01, 2024 | 4:46 pm

MO

Altria Group's shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided optimistic adjusted EPS guidance for FY24.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 4:45 pm